Vasilevska, Kristin
Preferred name
Vasilevska, Kristin
Official Name
Vasilevska, Kristin
Main Affiliation
Email
kristin.vasilevska@medf.ukim.edu.mk
32 results
Now showing 1 - 10 of 32
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Ефикасност и подносливост на цефподоксимот во амбулантското лекување на егзацербациите на хроничната опструктивна белодробна болест(Лекарска комора на Македонија, 2014); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Work-related asthma in automobile spray painters: two case reports(Walter de Gruyter GmbH, 2008-06); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Exercise-related respiratory symptoms and exercise-induced bronchoconstriction in industrial bakers(Informa UK Limited, 2013); ; ; ; In order to assess prevalence and characteristics of exercise-related respiratory symptoms (ERRS) and exercise-induced bronchoconstriction (EIB) in industrial bakery, the authors performed a cross-sectional study including 57 bakers and an equal number of office workers studied as a control. Evaluation of examined subjects included completion of a questionnaire, skin prick tests to common inhalant and occupational allergens, spirometry, and exercise and histamine challenge. The authors found a similar prevalence of ERRS and EIB in both bakers and controls. EIB was significantly associated with atopy, asthma, family history of asthma, and positive histamine challenge in either group, whereas in bakers it was closely related to sensitization to occupational allergens (p = .032). Bronchial reaction to exercise was significantly higher in bakers with EIB (25.7% vs 19.2%; p = .021). These findings suggest that occupational exposure in industrial bakery may accentuate bronchoconstrictive response to exercise. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Respiratory and nasal symptoms, immunological changes and lung function among petroleum refinery workers(Società italiana di medicina del lavoro, 2010); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Epidemiological Characteristics of Autism in Republic of Macedonia(Faculty of Philosophy, UKIM, Skopje, Macedonia, 2005); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Carbocysteine in the Management of Stable COPD: Are Its Antioxidant and Anti-Inflammatory Properties Clinically Relevant?(ID Design Press, 2017-12-27); ; ; The recent epidemiological and experimental evidence suggest possible antioxidant effect of carbocysteine in patients with chronic obstructive pulmonary disease (COPD).AIM: To assess efficacy and tolerability of carbocysteine in the management of stable COPD.METHODS: We performed an observational, non-randomized, open study (a real life study) including 87 patients with stable COPD (group B and D by combined COPD assessment) divided in two groups, examined group (EG) and control group (CG). All participants were treated with the regular treatment of the stable disease, but in the participants of the EG carbocysteine 1,500 mg daily was added to their regular treatment during the period of two months. The study protocol included completion of the COPD Assessment Test (CAT) and spirometric measurements at initial visit and at the end of the mentioned period.RESULTS: We found significantly lower mean value of the overall CAT score in the EG at the end of the study as compared to its mean value registered at initial visit (26.9 vs. 24.3; P = 0.007). In regard to certain CAT items, we found significantly lower values of the mean scores related to cough phlegm and sleep disturbances as compared to their mean scores at initial visit. In addition, the mean values of the overall CAT scores at initial visit and at the end of the study in controls were similar. In EG we found significantly higher mean value of the MEF 25-75 at the end of the study as compared to its mean value registered at initial visit (59.3% vs. 67.2%; P = 0.003). There was no significant difference in the mean values of other spirometric parameters at the end of the study as compared to their mean values at initial visit. In controls we registered similar values of all measured spirometric parameters at the end of the study as compared to their values registered at initial visit. Mild gastrointestinal manifestations were registered in 13.3% of the participants of the EG during the examined period.CONCLUSION: Our findings indicate positive effects of carbocysteine regarding the symptoms and lung function, as well as its good tolerability in the patients with stable COPD.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Asthma Control Test™ in Assessment of Clinical Asthma Control(ID Design Press, 2009-12-01); ; ; Snezana Risteska-KucBackground. The goal of asthma treatment is to achieve and maintain control of the disease. Objective. To assess validity and reliability of Asthma Control TestTM (ACT) as a patient-based tool for quantifying the control of the disease in the subjects with persistent asthma. Methods. A cross-sectional study including 396 subjects with persistent asthma drown from a population of treated patients was performed. Evaluation of the examined subjects included completion of the ACT, spirometry, and asthma specialist rating of control. Results. The mean derived ACT score in all study subjects was 19.2±3.3. Prevalence of the study subjects with totally controlled (TC), well-controlled (WC) and not well-controlled (NWC) asthma by derived ACT score was 9.1%, 43.2% and 47.7%, respectively. Results from the spirometry showed that in 45% of the study subjects FEV1 value was less than 80%. Prevalence of the study subjects with TC, WC and NWC asthma by asthma specialist rating was 8.1%, 41.1% and 50.7%, respectively. A strong correlation between the derived ACT scores and asthma specialist rating of control was observed (r = 0.51, P = 0.000). Conclusion. Our data confirm the usefulness of the ACT as a valid and reliable screening tool for asthma control. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Inert Cellulose Powder in the Treatment of Seasonal Allergic Rhinitis(Sunnyvale, Calif. : OMICS Pub. Group, 2017-01-27); ; ; Objective: To assess efficacy and safety of inert cellulose powder (ICP) in the treatment of mild seasonal allergic rhinitis (SAR). Methods: An observational, non-randomized, open study including 74 examinees suffering from mild SAR was conducted. The study subjects were divided in two groups, Group 1 (G1) and Group 2 (G2). The study subjects from G1 were treated 10 days with oral cetirizine and ICP, while the study subjects from G2 were treated 10 days only with oral cetirizine. The treatment outcomes were evaluated after five and 10 days by self-assessment of the symptoms on a five-point scale. Results: In both groups improvement of the symptoms five and 10 days after the treatment was registered. There was significantly higher prevalence of the G1 study subjects in the point 4 (“major relief, casual sneezing”) five days after beginning of the treatment (43.2% vs. 18.9%; P<0.05), as well as in the point 5 (“complete relief, without symptoms”) at the end of the treatment (56.7% vs. 27.0%; P<0.05). A low frequency of adverse effects was registered among examinees of both groups. Conclusion: The results obtained indicated high efficacy and safety of ICP in the treatment of mild SAR. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of passive smoking at work on respiratory symptoms, lung function, and bronchial responsiveness in never-smoking office cleaning women(Walter de Gruyter GmbH, 2009-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficacy and Tolerability of Various Antimicrobial Regimens in the Treatment of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Outpatients(ID Design Press, 2009-06-01); ; ; Risteska-Kuc, SnezanaObjective. To compare the efficacy and tolerability of different antibiotics empirically administered for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). Methods. We performed an observational, non-randomized, open-label study including 226 outpatients with exacerbations of chronic bronchitis and mild or moderate COPD, 123 males and 103 females, aged 24 to 81. All patients were followed up for 30 days, with an intermediate visits at 5 and 10 days at which they were asked about the duration of symptoms (increased expectoration, increased dyspnea and/or presence of purulent sputum) and the side-effects of the drug. Five antibiotic regimens were evaluated: amoxicillin/clavulanic acid 875 mg/125 mg twice daily for 10 days, cefuroxime 250 mg twice daily for 10 days, cefixime 400 mg once daily for 10 days, clarithromycin 500 mg twice daily for 10 days, and ciprofloxacin 500 mg twice daily for 10 days. Results. The clinical success rate, defined as a complete resolution or a return of the symptoms to the baseline severity, in the groups receiving amoxicillin/clavulanic acid, cefuroxime, cefixime, clarithromycin, and ciprofloxacin was 68.9%, 75.0%, 73.5%, 72.7%, and 77.1%, respectively. The mean time to relief of symptoms varied from 6.8 days with amoxicillin/clavulanic acid to 6.1 days with cefuroxime. Relapse within the first month was registered in the group receiving clarithromycin and ciprofloxacin (3.1% and 2.6%, respectively). The prevalence of the adverse events varied from 10.4% with ciprofloxacin, following by 8.9% for amoxicillin/clavulanic acid, 7.5% for cefixime, 6.8% with clarithromycin to 6.1% with cefuroxime. Conclusion. Our findings suggest high efficacy and safety of all studied regimens in the treatment of exacerbations of chronic bronchitis and COPD.